News

BI 764524 was well tolerated following intravitreal administration of single and multiple doses in the phase 1/2a trial, with signs pointing to early efficacy.

In this interview, Browning discusses his team’s trial data and the implications of the FDA’s decision to accept the supplemental new drug application for tapinarof as an eczema treatment.

Results showed the prevalence and treatment patterns for IgAN in select Asian Pacific countries and regions were not commonly available.

Devanand reviews lecanemab and the advent of blood biomarkers for dementia and Alzheimer's management at APA 2024.

Marmar explains what anticipated blood and molecular profiling of PTSD may provide psychiatrists treating patients.

Kane explains why newer long-acting injectables and clozapine may be under-utilized still in the management of schizophrenia.

In an interview with Andrew Chen, MD, he explained why patients might need to turn to more adverse event prone anxiety medications.

Despite often presenting to the hospital with similar non-psychiatric conditions, patients with schizophrenia often experience a more difficult care process than those without.

In an interview with Andrew Chen, MD, he discussed the first-line treatment for generalized anxiety disorder and when to take other alterative medication.

Four-year, phase 3 data from APA 2024 show olanzapine/samidorphan provided consistent antipsychotic efficacy and weight-related safety in patients with either schizophrenia or bipolar I disorder.

Extended follow-up of a phase 1/2 trial finds hydroxyurea dose optimization significantly improves clinical responses in children in sub-Saharan Africa with sickle cell.

These data shed light on several important findings related to perceptions of hair loss severity among specific groups with central centrifugal cicatricial alopecia and their QoL measures.

Results showed 46.45 and 72.74% increases in the global incidences of acute infection and HCV-related cirrhosis, respectively, in reproductive-age women.

Payal Kohli, MD, discusses how recent advancements have changed conversations surrounding modifiable cardiovascular risk and what it means for practitioners.

A nutritional supplement significantly improved the signs and symptoms of dry eye, including tear production and reduced ocular surface damage.

This analysis indicates that quantitative interstitial abnormalities may indicate alterations in lung tissue processes that can result in short- and long-term consequences as far as symptoms.

Findings showed the light microscopy pattern of glomerular injury and the intensity of mesangial C3 deposition may refine the histological assessment of IgAN.

The biosimilars month in review reflects ongoing efforts to address key challenges in rheumatic disease treatment.

This month's review focuses on digital technology use in ophthalmology, the association between vision impairment and mental health, and public health impacts in eye care.

These survey results indicate that young adults tended to embrace misconceptions regarding sun protection and positive views of tanning.

Findings suggest metformin and statins have a potective effect against HCC in patients with HCV who fail antiviral therapy.

Our April month in review for hematology breaks down the latest updates to the pipeline, mortality risk in people with sickle cell disease, and our newest multimedia offerings.

The April 2024 cardiology month in review spotlights FDA news and top updates from the American College of Cardiology 2024 Scientific Session.

These data suggest vaping poses potential threats to the development of the brain and organs, with teenagers being a predominant target due to surges in use.

A new study found specific sociodemographic factors were linked to 76.4% lower odds of adhering to topical therapy for psoriasis.

This month in review highlights top coverage of the latest news in nephrology, ranging from new clinical trial data in IgAN to research about kidney disease management.

An interim analysis of a phase 3 trial displays the effectiveness of prophylaxis with recombinant ADAMTS13, achieving approximately 100% of normal ADAMTS13 levels.

This sleep month in review features positive pipeline updates and treatments for improved sleep quality.